IL4 and diabetes mellitus: hASC and hASC-CM treatments were able to normalize cytokine levels, as demonstrated by the IFN-γ and IL-2 decrease (panels b and d, p < 0.001 vs STZ) and IL-10 and IL-4 increase when treatments were performed 6 weeks after diabetes induction and cytokines measured 8 weeks later (Fig. 7, panels f and h).